About Us
Purpose
Kardigan is on a mission to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve.
We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team who is driven to improve the lives of patients.
We are relentless in our pursuit to create novel medicines that modify the underlying causes of cardiovascular disease, advancing beyond symptom management toward functional cures.
By targeting the underlying drivers of disease, Kardigan is building a platform that integrates complementary drug candidates to deepen understanding of core cardiovascular pathways and enable the development of therapies across multiple underserved conditions.
“To create meaningful change for patients suffering from cardiovascular diseases, we need to think differently about how we develop new drugs. At Kardigan, we are uniting real-world patient data, AI insights, and deep cardiovascular expertise to advance therapies with the potential to transform outcomes.”
Kardigan has curated a diverse pipeline with three late-stage clinical programs, and each is designed to move beyond symptom management and aims to redefine treatment approaches where patients and their families need it most. Collectively, the programs create opportunities to generate new clinical insights and data that will fuel Kardigan’s ongoing R&D and discovery efforts beyond these three disease areas.
Supported by the integration of Prolaio’s AI and real-world data platform, Kardigan is enhancing its ability to generate insights that can inform clinical trial design and potentially reduce the time and cost to develop meaningful new medicines.